Fractyl Health (NASDAQ:GUTS - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect Fractyl Health to post earnings of ($0.45) per share for the quarter.
Fractyl Health (NASDAQ:GUTS - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.08). On average, analysts expect Fractyl Health to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Fractyl Health Stock Performance
Shares of GUTS traded up $0.01 during midday trading on Wednesday, reaching $1.51. The stock had a trading volume of 153,814 shares, compared to its average volume of 306,341. The firm has a market cap of $73.96 million, a PE ratio of -0.12 and a beta of 0.10. The firm has a 50 day simple moving average of $1.26 and a 200-day simple moving average of $1.78. Fractyl Health has a one year low of $0.87 and a one year high of $7.89. The company has a current ratio of 5.58, a quick ratio of 5.57 and a debt-to-equity ratio of 0.60.
Analysts Set New Price Targets
GUTS has been the topic of a number of recent analyst reports. Canaccord Genuity Group began coverage on Fractyl Health in a research report on Tuesday, April 15th. They set a "buy" rating and a $12.00 price target on the stock. Morgan Stanley dropped their price target on Fractyl Health from $18.00 to $10.00 and set an "overweight" rating on the stock in a research note on Monday, February 3rd.
Get Our Latest Report on Fractyl Health
Fractyl Health Company Profile
(
Get Free Report)
Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
See Also
Before you consider Fractyl Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fractyl Health wasn't on the list.
While Fractyl Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
